<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02652078</url>
  </required_header>
  <id_info>
    <org_study_id>Shockwave 1</org_study_id>
    <secondary_id>166137</secondary_id>
    <nct_id>NCT02652078</nct_id>
  </id_info>
  <brief_title>Shockwave Therapy in Lower Limb Intermittent Calf Claudication</brief_title>
  <acronym>SLICC</acronym>
  <official_title>Extracorporeal Shockwave Therapy in the Treatment of Intermittent Claudication Symptoms in Peripheral Vascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hull University Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Hull</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hull University Teaching Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral arterial disease is a common condition affecting approximately 64% of 56-77 year&#xD;
      olds. This condition restricts bloody supply to calf muscles. Pain occurs after walking a&#xD;
      short distance and increases in intensity until the person stops, where the pain then&#xD;
      gradually subsides. It can be limiting or occasionally debilitating and has been shown to&#xD;
      have considerable deleterious effects of patients quality of life. Shock wave therapy has&#xD;
      been shown to promote new blood vessel formation and improved healing amongst other findings.&#xD;
      This study aims to identify whether shock wave therapy that is applied to the calf muscles&#xD;
      causes such an effect to improve the blood supply to the calf muscles, reduce pain, improve&#xD;
      walking ability and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to compare the effects of extracorporeal shockwave therapy (ESWT) to placebo&#xD;
      with use of a sham control group on walking distances in subjects with lower limb&#xD;
      intermittent calf claudication. Extracorporeal shockwave therapy will be applied using the&#xD;
      PiezoWave2 shockwave system. All applications will be in adherence to the manufacturer's&#xD;
      instructions and provided by trained staff. The device will be targeted at the gastrocnemius&#xD;
      muscles of the affected lower leg for several minutes at each treatment session. Participants&#xD;
      in control group will undergo the identical process as if treatment were being given but with&#xD;
      the shockwaves not being administered and a sham device alternatively used. Participants will&#xD;
      have several assessments prior to and after the shockwave treatment in order to quantify the&#xD;
      effect. Assessments will include Maximum Walking Distance (MWD), Claudication Distance (CD)&#xD;
      and Quality of life questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 11, 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Walking Distance (MWD)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treadmill test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Claudication Distance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Distance covered prior to onset of any symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Ankle Brachial Pressure Index</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Patient reported walking distance</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of life [Short form 36(SF36)</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of life [EuroQoL (EQ5D)]</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject tolerance of treatment</measure>
    <time_frame>Week 4</time_frame>
    <description>Questionnaire including visual analogue pain scales</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham treatment in identical format to treatment arm but without shockwave production</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shockwave</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active shockwave treatment to calf muscle bulk</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extracorporeal shockwave therapy</intervention_name>
    <description>Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Shockwave</arm_group_label>
    <other_name>external shockwave</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with unilateral or bilateral intermittent calf claudication (stable for the&#xD;
             last 3 months).&#xD;
&#xD;
          -  Able to give written informed consent to participate in the study&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Able to adhere to protocol and attend all follow up appointments&#xD;
&#xD;
          -  Currently receiving &quot;best medical therapy&quot; - anti-platelet and statin medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current malignancy&#xD;
&#xD;
          -  Allergies or intolerances of either anti-platelet medication or statin therapy&#xD;
&#xD;
          -  Pregnancy (pregnancy test performed at screening if necessary)&#xD;
&#xD;
          -  Metal implant near to treatment area&#xD;
&#xD;
          -  Anti-coagulation medication (i.e. Warfarin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Chetter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hull and East Yorkshire Hospital Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Vascular Surgery Unit</name>
      <address>
        <city>Hull</city>
        <state>Yorkshire</state>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/29722640?dopt=Abstract</url>
    <description>Publication Link</description>
  </link>
  <results_reference>
    <citation>Green JL, Harwood AE, Smith GE, Das T, Raza A, Cayton T, Wallace T, Carradice D, Chetter IC. Extracorporeal shockwave therapy for intermittent claudication: Medium-term outcomes from a double-blind randomised placebo-controlled pilot trial. Vascular. 2018 Oct;26(5):531-539. doi: 10.1177/1708538118773618. Epub 2018 May 3.</citation>
    <PMID>29722640</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

